You are here

Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study.

TitleExceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study.
Publication TypeJournal Article
Year of Publication2020
AuthorsReiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ, Chen Y, Su Y, Myers AJ, Hardy J, Vonsattel JPaul, Younkin SG, Bennett DA, De Jager PL, Larson EB, Crane PK, C Keene D, M Kamboh I, Kofler JK, Duque L, Gilbert JR, Gwirtsman HE, Buxbaum JD, Dickson DW, Frosch MP, Ghetti BF, Lunetta KL, San Wang L-, Hyman BT, Kukull WA, Foroud T, Haines JL, Mayeux RP, Pericak-Vance MA, Schneider JA, Trojanowski JQ, Farrer LA, Schellenberg GD, Beecham GW, Montine TJ, Jun GR
Corporate AuthorsAlzheimer’s Disease Genetics Consortium
JournalNat Commun
Volume11
Issue1
Pagination667
Date Published2020 02 03
ISSN2041-1723
KeywordsAged, Aged, 80 and over, Alleles, Alzheimer Disease, Apolipoprotein E2, Apolipoprotein E3, Apolipoprotein E4, Brain, Female, Genetic Association Studies, Genetic Predisposition to Disease, Genotype, Homozygote, Humans, Male, Middle Aged, Neuropathology, Probability
Abstract

Each additional copy of the apolipoprotein E4 (APOE4) allele is associated with a higher risk of Alzheimer's dementia, while the APOE2 allele is associated with a lower risk of Alzheimer's dementia, it is not yet known whether APOE2 homozygotes have a particularly low risk. We generated Alzheimer's dementia odds ratios and other findings in more than 5,000 clinically characterized and neuropathologically characterized Alzheimer's dementia cases and controls. APOE2/2 was associated with a low Alzheimer's dementia odds ratios compared to APOE2/3 and 3/3, and an exceptionally low odds ratio compared to APOE4/4, and the impact of APOE2 and APOE4 gene dose was significantly greater in the neuropathologically confirmed group than in more than 24,000 neuropathologically unconfirmed cases and controls. Finding and targeting the factors by which APOE and its variants influence Alzheimer's disease could have a major impact on the understanding, treatment and prevention of the disease.

DOI10.1038/s41467-019-14279-8
Pubmed Linkhttps://www.ncbi.nlm.nih.gov/pubmed/32015339?dopt=Abstract
page_expoInternal
Alternate JournalNat Commun
PubMed ID32015339
PubMed Central IDPMC6997393
Grant ListMR/L501542/1 / MRC_ / Medical Research Council / United Kingdom
RF1 AG051504 / AG / NIA NIH HHS / United States
P30 AG010161 / AG / NIA NIH HHS / United States
R01 AG061796 / AG / NIA NIH HHS / United States
U01 AG046139 / AG / NIA NIH HHS / United States
G0901254 / MRC_ / Medical Research Council / United Kingdom
R01 AG064877 / AG / NIA NIH HHS / United States
P30 AG010124 / AG / NIA NIH HHS / United States
U01 AG058922 / AG / NIA NIH HHS / United States
P30 AG010133 / AG / NIA NIH HHS / United States
G-0907 / PUK_ / Parkinson's UK / United Kingdom
G0701075 / MRC_ / Medical Research Council / United Kingdom
U01 AG032984 / AG / NIA NIH HHS / United States
P30 AG062421 / AG / NIA NIH HHS / United States
UL1 TR002369 / TR / NCATS NIH HHS / United States
P50 AG008702 / AG / NIA NIH HHS / United States
U24 AG056270 / AG / NIA NIH HHS / United States
R01 AG017917 / AG / NIA NIH HHS / United States
P30 AG062429 / AG / NIA NIH HHS / United States
RF1 AG054023 / AG / NIA NIH HHS / United States
P50 AG005136 / AG / NIA NIH HHS / United States
P01 AG019724 / AG / NIA NIH HHS / United States
P30 AG066462 / AG / NIA NIH HHS / United States
P30 AG062715 / AG / NIA NIH HHS / United States
RF1 AG015473 / AG / NIA NIH HHS / United States
P30 AG019610 / AG / NIA NIH HHS / United States
MR/N026004/1 / MRC_ / Medical Research Council / United Kingdom
RF1 AG057902 / AG / NIA NIH HHS / United States
R01 AG015819 / AG / NIA NIH HHS / United States

Theme by Danetsoft and Danang Probo Sayekti inspired by Maksimer